Effect of bevacizumab adjuvant chemotherapy on recurrent ovarian cancer and its infiuences on tumor markers and inflammatory factors
Objective To explore the effect of bevacizumab adjuvant chemotherapy on recurrent ovarian cancer and its influences on tumor markers and inflammatory factors.Methods A total of 98 patients with recurrent ovarian cancer admitted in the oncology department from January 2018 to December 2021 were selected as the research objects.According to different treatment methods,the patients were divided into control group and experimental group,with 49 cases in each group.The control group was treated with paclitaxel/carboplatin(PC),and the experimental group was treated with bevacizumab on this basis.The therapeutic effects of the two groups were compared.Results The disease remission rate and disease control rate of the experimental group were higher than those of the control group(P<0.05).After treatment,the levels of vascular endothelial growth factor(VEGF)and macrophage migration inhibitory factor(MIF)in the experimental group were lower than those in the control group(P<0.05).After treatment,the levels of carbohydrate antigen 125(CA125),carcinoembryonic antigen(CEA),carbohydrate antigen 199(CA199)and interleukin-6(IL-6)in the experimental group were lower than those in the control group,and the level of interferon-γ(IFN-γ)was higher than that in the control group(P<0.05).Conclusion Bevacizumab adjuvant chemotherapy in the treatment of recurrent ovarian cancer is effective,it can reduce the level of tumor angiogenesis indicators and improve the levels of tumor markers and inflammatory factors,which is worthy of clinical promotion and application.
paclitaxelcarboplatinbevacizumabrecurrent ovarian cancer
NETL
NSTL
万方数据
维普
